In our study, we demonstrated that using the BEAMing technology, testing for 21 oncogenic mutations in BRAF, EGFR, KRAS and PIK3CA genes in the plasma cfDNA of patients with advanced cancers referred for treatment with experimental targeted therapies, is feasible. The gene discussed is PIK3CA; the disease is cancer.